BRIGHTWAY
4.11.2021 18:07:09 CET | Business Wire | Press release
SUZHOU BRIGHTWAY released the latest flagship Electric Scooter NAVEE N65 on Xiaomi Youpin crowdfunding website, and raised more than €430,000 successfully.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104006077/en/
BRIGHTWAY has a professional design and R&D team with rich experience in micro-mobility. Based on the thorough understanding of customers’ requirements and pain points, as well as the full consideration of practicality, safety and comfort at the stage of design, BRIGHTWAY team finally launched NAVEE N65 with the following key features, making the N65 perfect and the most suitable for commute or joy ride.
65KM Ultra-long Range : Travelling up to 65 km on a single charge, the N65 can make the charging frequency from one time per day to one time per week for the customers with short distance commuting within 10km.
10 Inch Big Tires: In order to deliver extremely comfortable and smooth riding experience for riders, the N65 is equipped 10-inch big off-road pneumatic tires.
Rated Power 500watt Brushless Motor: It improves the climbing performance up to 25%, and supports three different speed level (1st level to 15km/h, 2nd level to 25km/h, 3rd level to 32km/h). The maximum speed can reach 32 km/h. (Noted: The maximum speed varies according to the laws and regulations of different regions, please refer to the requirements of the laws and regulations)
Double Rotation Folding System: With innovative design of folding neck and handlebar, the N65 makes the pre-assembling and folding more convenient.
Features:
- Ultra-long range up to 65 km;
- Innovative design of double rotation folding system;
- 25% superb uphill climbing ability;
- 10 inch off-road pneumatic tires;
- Rated power 500watt brushless motor;
- Max loading weight 120kg;
- 17cm wide magnesium alloy deck;
- Front E-ABS brake with rear disc brake;
- Separated big HMI;
- Three speed levels;
- Support cruise control and energy recovery with APP.
- Ultra-bright front light
In middle November, NAVEE N65 will be launched at European market with only priced at €649. And the limited-time promotion price is just €599.
About BRIGHTWAY
SUZHOU BRIGHTWAY Intelligent Technology Co., Ltd is an innovative high-tech enterprise focusing on R&D, production and distribution of E-scooters and E-bikes. Equipped with advanced technology and strong R&D strength, SUZHOU BRIGHTWAY Intelligent Technology Co., Ltd. now is also an emerging Xiaomi ecological chain company.
For more information, please visit http://navee-tech.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Announces Key Executive Appointments for the Next Phase of Delivery15.6.2026 23:20:00 CEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 18:18:00 CEST | Press release
A global platform mobilizing expertise and collective action to advance shared digital priorities The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies an
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 18:00:00 CEST | Press release
- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease drive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
